TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
2월 04, 2026
2 min read
10

U.S. premarket trading showed mixed results as the corporate earnings season continues. Advanced Micro Devices (AMD) saw a significant drop of 9.5%, while pharmaceutical giant Eli Lilly (LLY) surged by 6.5%, highlighting a market driven by individual company performance.
While the broader market indicated a slight upward trend, specific sectors faced volatility based on quarterly reports. The technology and healthcare sectors were particularly in focus. AMD's decline was prompted by a forecast for a slight dip in quarterly revenue, fueling concerns about its competitive standing against Nvidia in the AI chip market. In contrast, Super Micro Computer (SMCI) gained 10% after raising its revenue forecast on strong AI server demand.
In the healthcare sector, Eli Lilly's stock rose sharply after the company issued an upbeat annual sales forecast, driven by high demand for its weight-loss drug. Conversely, Novo Nordisk (NVO) fell 3% after warning of lower sales in 2026 due to pricing pressures. Other notable movers included Uber (UBER), which fell 9% on disappointing earnings, and Chipotle (CMG), which dropped 5.5% due to declining customer traffic.
The market is currently navigating a period where company-specific news and future guidance heavily influence investor sentiment. Traders are closely watching earnings reports from major corporations to gauge the health of various industries and predict future market direction.
Q: Why did AMD stock fall significantly?
A: AMD forecasted a slight dip in quarterly revenue, which raised concerns among investors about its ability to effectively compete with Nvidia in the booming AI market.
Q: What was the main driver for Eli Lilly's stock surge?
A: Eli Lilly's stock increased after the company provided a strong sales forecast for the year, largely due to robust demand for its popular weight-loss drug.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles